Association of circulating levels of apolipoprotein M and adiponectin with insulin sensitivity in overweight subjects and obese patients with weight loss surgery
暂无分享,去创建一个
J. Ferrières | P. de Souto Barreto | N. Viguerie | C. Moro | M. Croyal | J. Ruidavets | R. Valéro | M. Maraninchi | G. Combes | J. Raffin | L. Martinez | B. Perret
[1] M. Krempf,et al. Bariatric Surgery Improves the Atherogenic Profile of Circulating Methylarginines in Obese Patients: Results from a Pilot Study , 2021, Metabolites.
[2] S. Shikora,et al. Bariatric Surgery Survey 2018: Similarities and Disparities Among the 5 IFSO Chapters , 2021, Obesity Surgery.
[3] G. Shulman,et al. Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice , 2020, Proceedings of the National Academy of Sciences of the United States of America.
[4] J. Ruidavets,et al. A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: comparison with conventional ELISA , 2020, medRxiv.
[5] Dan Liu,et al. Interaction Between Apolipoprotein M Gene Single-Nucleotide Polymorphisms and Obesity and its Effect on Type 2 Diabetes Mellitus Susceptibility , 2020, Scientific Reports.
[6] D. Rader,et al. Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure , 2020, Circulation.
[7] N. Viguerie,et al. Apolipoprotein M: new connections with diet, adipose tissue and metabolic syndrome. , 2019, Current opinion in lipidology.
[8] T. Funahashi,et al. Adiponectin, a unique adipocyte-derived factor beyond hormones. , 2019, Atherosclerosis.
[9] J. Heeren,et al. The endocrine function of adipose tissues in health and cardiometabolic disease , 2019, Nature Reviews Endocrinology.
[10] A. Valsesia,et al. Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction. , 2019, The American journal of clinical nutrition.
[11] C. Christoffersen,et al. Apolipoprotein M/sphingosine-1-phosphate: novel effects on lipids, inflammation and kidney biology , 2019, Current opinion in lipidology.
[12] P. Formisano,et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications , 2019, International journal of molecular sciences.
[13] Liu Yang,et al. Correlation Between Apolipoprotein M and Inflammatory Factors in Obese Patients , 2018, Medical science monitor : international medical journal of experimental and clinical research.
[14] S. Swendeman,et al. An engineered S1P chaperone attenuates hypertension and ischemic injury , 2017, Science Signaling.
[15] Yajing Wang,et al. Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification , 2017, Trends in Endocrinology & Metabolism.
[16] Puhong Zhang,et al. Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus: an independent case–control study , 2016, Lipids in Health and Disease.
[17] P. Scherer,et al. Adiponectin, the past two decades. , 2016, Journal of molecular cell biology.
[18] M. Fasshauer,et al. Adipokines in health and disease. , 2015, Trends in pharmacological sciences.
[19] C. Christoffersen,et al. Apolipoprotein M in lipid metabolism and cardiometabolic diseases , 2015, Current opinion in lipidology.
[20] J. Ruidavets,et al. Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study[S] , 2013, Journal of Lipid Research.
[21] Richard N Bergman,et al. Gastrointestinal hormones and bariatric surgery‐induced weight loss , 2013, Obesity.
[22] H. Buchwald,et al. Metabolic/Bariatric Surgery Worldwide 2011 , 2013, Obesity Surgery.
[23] J. Ruidavets,et al. Adiponectin and Long-Term Mortality in Coronary Artery Disease Participants and Controls , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[24] Rennian Wang,et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes , 2012, Nature Medicine.
[25] M. Whooley,et al. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. , 2012, Atherosclerosis.
[26] B. Dahlbäck,et al. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. , 2011, Atherosclerosis.
[27] B. Wolffenbuttel,et al. Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. , 2010, Atherosclerosis.
[28] G. Watts,et al. Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. , 2010, Atherosclerosis.
[29] B. Dahlbäck,et al. Apolipoprotein M predicts pre‐β‐HDL formation: studies in type 2 diabetic and nondiabetic subjects , 2009, Journal of internal medicine.
[30] B. Dahlbäck,et al. Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[31] B. Dahlbäck,et al. Apolipoprotein M affecting lipid metabolism or just catching a ride with lipoproteins in the circulation? , 2009, Cellular and Molecular Life Sciences.
[32] N. Abdella,et al. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes , 2007, International Journal of Obesity.
[33] Shinji Kihara,et al. Adiponectin: a key adipocytokine in metabolic syndrome. , 2006, Clinical science.
[34] David Couper,et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2004, Diabetes.
[35] R. Vigneri,et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. , 2004, The Journal of clinical endocrinology and metabolism.
[36] T. Ogihara,et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. , 2004, Journal of the American College of Cardiology.
[37] K. Clément,et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. , 2002, Human molecular genetics.